Resigratinib

Overview

Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR 1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR , blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis . Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer ).

Application

Products | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > FGFR

Product Information

• Catalog No.: HY-156632
• CAS No.: 2750709-91-0
• Molecular Formula: C26H27F2N7O3
• Molecular Weight: 523.53
• Purity: 99.43%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (9.55 mM); Clear solution
• Availability: In-stock

Source

Original product source